#AMIX

StockTitan

@stocktitan.net

1 week ago

Autonomix Medical Selected for Best Innovation Competition at CRT 2026 Autonomix Medical (NASDAQ: AMIX) was selected for an oral presentation in the CRT 2026 Best Innovation Competition for its talk “Illuminating The Nervous System With Transvascular Precision-guided Technology.”CEO Brad Hauser will present on March 9, 2026, 4:19–4:27 PM ET in the International Ballroom – West, highlighting the company’s transvascular, nerve-targeted technology and its clinical relevance.

#AMIX Autonomix Medical Selected for Best Innovation Competition at CRT 2026

www.stocktitan.net/news/AMIX/autonomix-medi...

PenkeTrading

@penkeinvesting.bsky.social

2 weeks ago

Fundamental analysis of $AMIX (Autonomix Medical, Inc.) based on financial data and reported results.

#AMIX

Manu TooManySecrets

@sotomonte.net

1 month ago

#Amiga #UNIX (aka #Amix)

www.amigaunix.com

StockTitan

@stocktitan.net

2 months ago

Autonomix Medical, Inc. Granted European Patent on Platform Technology Enabling Precision Nerve-Targeted Therapies in Cardiology Autonomix Medical (NASDAQ: AMIX) announced the European Patent Office granted EP4230133 on Dec 30, 2025 for “Controlled and Precise Treatment of Cardiac Tissues.”The patent covers systems, devices, and methods that sense autonomic/cardiac signals, map targets, and deliver closed-loop, feedback-driven neuromodulation, denervation, and/or ablation to precisely treat cardiac tissues. The grant complements U.S. Patent No. 12,369,852 and sits alongside the company’s stated IP portfolio of over 80 issued patents and 39 pending applications. The release highlights potential applications across arrhythmias, heart failure, hypertension (including renal–cardiac nerve interplay), ischemia/angina, and plaque/inflammation modulation.

#AMIX Autonomix Medical, Inc. Granted European Patent on Platform Technology Enabling Precision Nerve-Targeted Therapies in Cardiology

www.stocktitan.net/news/AMIX/autonomix-medi...

StockTitan

@stocktitan.net

2 months ago

Autonomix Medical, Inc. (NASDAQ: AMIX) Highlights Expanding IP Portfolio and Multi-Indication Platform Strategy in Virtual Investor CEO Connect Segment Autonomix Medical (NASDAQ: AMIX) participated in a Virtual Investor CEO Connect segment on Dec 23, 2025. CEO Brad Hauser outlined two strategic priorities:Strengthening intellectual property to protect and expand the company’s platform.Evaluating multi‑indication opportunities beyond pancreatic cancer, including potential applications in cardiovascular, pulmonary, and interventional pain management.The CEO segment is available online for investors to review.

#AMIX Autonomix Medical, Inc. (NASDAQ: AMIX) Highlights Expanding IP Portfolio and Multi-Indication Platform Strategy in Virtual Investor CEO Connect Segment

www.stocktitan.net/news/AMIX/autonomix-medi...

StockTitan

@stocktitan.net

2 months ago

Autonomix Medical, Inc. Announces Abstract Selected for Poster Presentation at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium Autonomix Medical (NASDAQ: AMIX) announced its abstract was accepted for a poster presentation at the 2026 ASCO Gastrointestinal Cancers Symposium in San Francisco, CA, January 8-10, 2026.The poster, titled "Pain mitigation in pancreatic adenocarcinoma: A long-term analysis of denervation via transvascular RF energy-based ablation," is Abstract 693 and will be presented by Robert S. Schwartz, MD, Chief Medical Officer. Session: Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract. Presentation times: January 9, 2026, 11:30 AM–1:00 PM and 5:00 PM–6:00 PM PST.

#AMIX Autonomix Medical, Inc. Announces Abstract Selected for Poster Presentation at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium

www.stocktitan.net/news/AMIX/autonomix-medi...

StockTitan

@stocktitan.net

3 months ago

Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment Highlighting Continued Execution and Strategic Growth Autonomix Medical (NASDAQ: AMIX) published a new CEO Corner segment on Nov 26, 2025.In the segment, President and CEO Brad Hauser discussed two priorities: protecting the company’s platform via intellectual property, and exploring expansion beyond its initial pancreatic cancer focus into potential cardiovascular, pulmonary, and chronic pain targets.The segment is available on the company website for investors and stakeholders seeking management commentary on strategy and pipeline direction.

#AMIX Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment Highlighting Continued Execution and Strategic Growth

www.stocktitan.net/news/AMIX/autonomix-medi...

StockTitan

@stocktitan.net

3 months ago

Autonomix Medical, Inc. Announces Pricing of $5.0 Million Private Placement Priced At The Market Under Nasdaq Rules Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it has entered into a securities purchase agreement with a single

#AMIX Autonomix Medical, Inc. Announces Pricing of $5.0 Million Private Placement Priced At The Market Under Nasdaq Rules

www.stocktitan.net/news/AMIX/autonomix-medi...

Stock Master

@stockmaster70.bsky.social

3 months ago

📢 Stocks Trending NOW: #NFLX #GOOGL #GOOG #GNS #QUBT #AMIX #DVLT #XPEV #SGML #DELL

StockTitan

@stocktitan.net

3 months ago

Autonomix Medical, Inc. Reports Positive Subgroup Results Demonstrating Sustained Improvements in Quality of Life from Post Hoc Analysis of Pancreatic Cancer PoC Study Autonomix Medical (NASDAQ: AMIX) announced a post-hoc subgroup analysis of its first-in-human PoC 1 study reporting sustained, clinically meaningful quality-of-life gains after targeted transvascular nerve ablation for severe pancreatic cancer pain.Key numeric findings: symptom scores improved 14.53 points at 4–6 weeks (n=9) and 26.07 points at 3 months (n=6); functionality rose 8.15 and 25.56 points; global QOL improved 8.33 and 18.06 points. Stage 4/metastatic subgroup exceeded EORTC ≥10-point meaningful-change thresholds at multiple timepoints.The company said results will inform its multicenter U.S. clinical trial planned to start in 2026.

#AMIX Autonomix Medical, Inc. Reports Positive Subgroup Results Demonstrating Sustained Improvements in Quality of Life from Post Hoc Analysis of Pancreatic Cancer PoC Study

www.stocktitan.net/news/AMIX/autonomix-medi...

Thiard News@F4F

@newsen.bsky.social

4 months ago

Ielove Park Introduces Advanced Parking Management System for Amix Corporation Ielove Park has launched its innovative parking management service for Amix Corporation, enhancing the customer experience and streamlining operations.

Ielove Park Introduces Advanced Parking Management System for Amix Corporation #Japan #Tokyo #parking #Ielove #Amix

StockTitan

@stocktitan.net

5 months ago

Autonomix Medical, Inc. Granted U.S. Patent on Platform Technology Enabling Precision Nerve-Targeted Therapies in Cardiology With over 120 issued and pending patent applications, Autonomix is building a comprehensive, global IP portfolio in nerve-sensing and modulation Newly issued patent strengthens the Company’s strategic position in a multi-billion-dollar market opportunity and unlocking potential across

#AMIX Autonomix Medical, Inc. Granted U.S. Patent on Platform Technology Enabling Precision Nerve-Targeted Therapies in Cardiology

www.stocktitan.net/news/AMIX/autonomix-medi...

StockTitan

@stocktitan.net

5 months ago

Medical Device Pioneer Autonomix Medical Details Nerve Treatment Progress, Sets 2026 U.S. Trial Launch Autonomix Medical CEO Brad Hauser provides insights on post hoc analysis from first-in-human proof-of-concept study and preparations for upcoming U.S. clinical trials in nerve-targeted treatments.

#AMIX Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment

www.stocktitan.net/news/AMIX/autonomix-medi...

StockTitan

@stocktitan.net

5 months ago

First-in-Class Nerve Treatment: Autonomix Medical Advances FDA Path with Critical GLP Study Launch Medical device company Autonomix initiates FDA-required GLP study for nerve-targeted cancer pain treatment. Plans IDE submission and clinical trials in 2026 for De Novo FDA application.

#AMIX Autonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study for Sensing and RF Ablation System 

www.stocktitan.net/news/AMIX/autonomix-medi...

StockTitan

@stocktitan.net

6 months ago

Revolutionary Nerve-Targeted Pain Treatment: Autonomix Medical Presents First Human Trial Results at CIRSE 2025 Autonomix Medical's first-in-human proof-of-concept study on transvascular RF ablation for pancreatic cancer pain to be featured at CIRSE 2025 Congress in Barcelona, Sept 15.

#AMIX Autonomix Medical, Inc. Announces Abstract Accepted for Podium Presentation at the 2025 CIRSE Annual Congress

www.stocktitan.net/news/AMIX/autonomix-medi...

StockTitan

@stocktitan.net

6 months ago

100% Zero Opioid Use: Autonomix Medical's Nerve Technology Shows Sustained Pain Reduction in Clinical Trial Medical device company Autonomix (NASDAQ: AMIX) reports post-hoc analysis of PoC 1 trial showing sustained pain reduction, quality of life improvements, and complete elimination of opioid usage.

#AMIX Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment

www.stocktitan.net/news/AMIX/autonomix-medi...

StockTitan

@stocktitan.net

6 months ago

66% Pain Reduction: Autonomix Medical's Breakthrough Device Eliminates Opioid Use in Cancer Patients Autonomix's nerve ablation technology achieves 5.08 VAS pain reduction in pancreatic cancer patients. 100% of responders opioid-free at 3 months, with 76.5% improvement in quality of life.

#AMIX Autonomix Medical, Inc. Demonstrates Sustained Pain Reduction, Quality of Life Gains and 100% Zero Opioid Use in Longer-Term Post Hoc Analysis from PoC 1 Study

www.stocktitan.net/news/AMIX/autonomix-medi...

StockTitan

@stocktitan.net

6 months ago

Revolutionary Neural Sensing Catheter: Autonomix Medical Wins EU Patent for First-in-Class Technology Medical device company Autonomix secures EU patent for real-time neural sensing catheter technology. Portfolio now includes 80 patents covering cardiovascular, renal, and neurotherapy applications.

#AMIX Autonomix Medical, Inc. Granted New European Patent for First-in-Class Catheter-Based Technology

www.stocktitan.net/news/AMIX/autonomix-medi...

StockTitan

@stocktitan.net

7 months ago

Revolutionary Nerve Sensing Catheter Heads to Clinical Trials, Promising Precise Pain Treatment Autonomix's microchip-based catheter enables real-time nerve mapping from within blood vessels, targeting pancreatic cancer pain treatment. FDA trial preparations advance. Learn more.

#AMIX Autonomix Medical, Inc. Finalizes Design Review of First-Ever Intravascular Nerve Sensing Catheter in Key Step Toward U.S. Clinical Studies

www.stocktitan.net/news/AMIX/autonomix-medi...

StockTitan

@stocktitan.net

7 months ago

Autonomix Medical CEO Shares Exclusive Insights on Revolutionary Nervous System Technology Future Watch Autonomix CEO Brad Hauser discuss breakthrough nervous system treatment technology and his vision for revolutionizing medical diagnostics. Access insights now.

#AMIX Autonomix Medical, Inc. Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

www.stocktitan.net/news/AMIX/autonomix-medi...

StockTitan

@stocktitan.net

7 months ago

Medical Device Pioneer Autonomix Secures $2.5M Fresh Capital as Investors Exercise Warrants Nerve treatment innovator raises $2.5M through warrant exercise at $1.723 per share, strengthening working capital position. See financing details.

#AMIX Autonomix Medical, Inc. Exercise of Warrants for $2.5 Million Gross Proceeds

www.stocktitan.net/news/AMIX/autonomix-medi...

StockTitan

@stocktitan.net

7 months ago

Autonomix Medical, Inc. Granted New U.S. Patent to Advance Minimally Invasive, Nerve-Focused Treatments Across High-Need Indications With over 80 issued patents and 40 pending patent applications, Autonomix is building a comprehensive IP portfolio in nerve-sensing and modulation, strengthening its strategic position in a multi-billion-dollar market opportunity and unlocking potential across cardiovascular, renal, and other

#AMIX Autonomix Medical, Inc. Granted New U.S. Patent to Advance Minimally Invasive, Nerve-Focused Treatments Across High-Need Indications

www.stocktitan.net/news/AMIX/autonomix-medi...

StockTitan

@stocktitan.net

8 months ago

Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment Autonomix Medical (NASDAQ: AMIX), a medical device company focused on precision nerve-targeted treatments, has released a new CEO Corner segment featuring CEO Brad Hauser. The segment, now available on the company's website, discusses details about the company's recently announced planned follow-on market expansion study phase (PoC 2) of its proof-of-concept trial.

#AMIX Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment

www.stocktitan.net/news/AMIX/autonomix-medi...

StockTitan

@stocktitan.net

8 months ago

Autonomix Medical Expands Revolutionary Cancer Pain Treatment to New Indications, Doubles Market Potential Just treated first patient in expanded trial targeting liver, gallbladder cancer pain. Doubles addressable market beyond pancreatic cancer. See growth strategy.

#AMIX Autonomix Medical, Inc. Treats First Patient in Follow-On Market Expansion Phase (“PoC 2”) of Proof-of-Concept Human Clinical Study

www.stocktitan.net/news/AMIX/autonomix-medi...

StockTitan

@stocktitan.net

8 months ago

Revolutionary Patent: Autonomix Medical's New Nerve Treatment Could Transform Pain Management New patent strengthens Autonomix's precision nerve treatment platform. Advanced catheter technology targets chronic pain and hypertension. Clinical trials start 2025. Learn more.

#AMIX Autonomix Medical, Inc. Granted New U.S. Patent for Innovative Catheter-Based Platform Technology

www.stocktitan.net/news/AMIX/autonomix-medi...

The Oasis BBS

@theoasisbbs.bsky.social

8 months ago

Exploring the A3070 Tape Drive - The Oasis BBS Discover the rare A3070 tape drive for the Amiga 3000, a SCSI device built for Commodore UNIX. Restored by Chris Edwards Restoration.

Exploring the A3070 Tape Drive
#Amiga3000 #A3070 #RetroComputing #ChrisEdwardsRestoration #CommodoreUNIX #AMIX #SCSI #TapeDrive #VintageTech

theoasisbbs.com/exploring-th...

StockTitan

@stocktitan.net

9 months ago

Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain Autonomix Medical (NASDAQ: AMIX) has received Ethics Committee authorization from Uzbekistan's Ministry of Health to expand its proof-of-concept human clinical trial (PoC 2) for cancer pain treatment. Building on successful initial results in pancreatic cancer pain, the company will now evaluate its proprietary ablation technology for broader visceral cancer applications. The PoC 2 study, set to begin enrollment in June 2025, aims to double the addressable market by including additional visceral cancers affecting the Celiac Plexus and earlier-stage pancreatic cancers. Initial trial results showed significant pain reduction, decreased opioid use, and improved quality of life. The technology platform shows potential for multiple applications beyond cancer pain, including cardiology, hypertension, and chronic pain management.

#AMIX Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain

www.stocktitan.net/news/AMIX/autonomix-medi...